These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32824587)

  • 21. Human immunodeficiency virus type 2 long terminal repeat: analysis of regulatory elements.
    Arya SK; Gallo RC
    Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9753-7. PubMed ID: 2849115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of tat gene and long terminal repeat region of human immunodeficiency virus type-1 detected among the injecting drug users (IDUs) of Manipur, India: identification of BC recombinants.
    Mullick R; Sengupta S; Sarkar K; Chakrabarti S
    Virus Res; 2010 Feb; 147(2):195-201. PubMed ID: 19896991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.
    Schafer SL; Vlach J; Pitha PM
    J Virol; 1996 Oct; 70(10):6937-46. PubMed ID: 8794337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation.
    Zhang HS; Sang WW; Wang YO; Liu W
    J Cell Biochem; 2010 Aug; 110(6):1464-70. PubMed ID: 20506278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short communication: a single step assay for rapid evaluation of inhibitors targeting HIV type 1 Tat-mediated long terminal repeat transactivation.
    Chande AG; Baba M; Mukhopadhyaya R
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):902-6. PubMed ID: 21878060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral components.
    Likhoshvai VA; Khlebodarova TM; Bazhan SI; Gainova IA; Chereshnev VA; Bocharov GA
    BMC Genomics; 2014; 15 Suppl 12(Suppl 12):S1. PubMed ID: 25564443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human immunodeficiency virus type 2 (HIV-2) trans-activator (Tat): functional domains and the search for trans-dominant negative mutants.
    Arya SK
    AIDS Res Hum Retroviruses; 1993 Sep; 9(9):839-48. PubMed ID: 8257633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation.
    Zhang HS; Li HY; Zhou Y; Wu MR; Zhou HS
    Free Radic Biol Med; 2009 Aug; 47(3):261-8. PubMed ID: 19409485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human immunodeficiency virus type 1 genome activation induced by human T-cell leukemia virus type 1 Tax protein is through cooperation of NF-kappaB and Tat.
    Cheng H; Tarnok J; Parks WP
    J Virol; 1998 Aug; 72(8):6911-6. PubMed ID: 9658145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interplay between viral Tat protein and c-Jun transcription factor in controlling LTR promoter activity in different human immunodeficiency virus type I subtypes.
    van der Sluis RM; Derking R; Breidel S; Speijer D; Berkhout B; Jeeninga RE
    J Gen Virol; 2014 Apr; 95(Pt 4):968-979. PubMed ID: 24447950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1.
    Viglianti GA; Mullins JI
    J Virol; 1988 Dec; 62(12):4523-32. PubMed ID: 2846868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variation and function of the HIV-1 Tat protein.
    Spector C; Mele AR; Wigdahl B; Nonnemacher MR
    Med Microbiol Immunol; 2019 Apr; 208(2):131-169. PubMed ID: 30834965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.
    Lin MH; Apolloni A; Cutillas V; Sivakumaran H; Martin S; Li D; Wei T; Wang R; Jin H; Spann K; Harrich D
    J Virol; 2015 May; 89(9):4827-36. PubMed ID: 25673710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein E isoform dependently affects Tat-mediated HIV-1 LTR transactivation.
    Khan N; Datta G; Geiger JD; Chen X
    J Neuroinflammation; 2018 Mar; 15(1):91. PubMed ID: 29558961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures.
    Antell GC; Dampier W; Aiamkitsumrit B; Nonnemacher MR; Jacobson JM; Pirrone V; Zhong W; Kercher K; Passic S; Williams JW; Schwartz G; Hershberg U; Krebs FC; Wigdahl B
    Retrovirology; 2016 May; 13(1):32. PubMed ID: 27143130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV Tat protein requirements for transactivation and repression of transcription are separable.
    Brown JA; Howcroft TK; Singer DS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jan; 17(1):9-16. PubMed ID: 9436753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
    Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
    Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR.
    Van Duyne R; Easley R; Wu W; Berro R; Pedati C; Klase Z; Kehn-Hall K; Flynn EK; Symer DE; Kashanchi F
    Retrovirology; 2008 May; 5():40. PubMed ID: 18498648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.